EU Investigates Allegations Against Roche

Before you go, we thought you'd like these...
Before you go close icon

Europe's drug and pharmaceutical regulator, the European Medicines Agency (EMA), announced today that it has launched an investigation into Swiss pharmaceutical company Roche(NASDAQOTH: RHHBY) over allegations that the company failed to report side effects of its products.

The agency will look at whether the company upheld legal responsibilities to ensure its 19 products are safe for European markets, according to an EMA press release.

The investigation comes after a similar action by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), which first pointed out potential flaws  in Roche's actions.


The EMA will pass on any findings to the European Commission, which could levy fines of up to 5% of all Roche's European Union sales.

Investigators from the MHRA identified up to 80,000 possible reports of side effects that the company hadn't handled properly. The claims include some of the company's biggest sellers, such as the influenza drug Tamiflu and cancer drug Avastin.

Roche said it was cooperating with authorities, and the EMA said  that all the company's drugs remained authorized for sale and use.

The article EU Investigates Allegations Against Roche originally appeared on Fool.com.

Dan Carroll has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners